Mizuho analyst Ann Hynes revisited her thesis on the potential for a leveraged buyout of Acadia Healthcare and updated her sensitivity analysis to $48 per share from $36 previously, which assumes more aggressive pro-forma leverage assumptions. The analyst still thinks an LBO of Acadia is a possibility but sees a maximum takeout price at $48 per share given the company’s current debt level. Acadia closed yesterday up 49c to $40.43. Hynes keeps a Neutral rating on the shares with a $37 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.